Agarwood as a potential therapeutic for Alzheimer's disease: Mechanistic insights and target identification.

IF 1.5 Q3 PHARMACOLOGY & PHARMACY Drug Discoveries and Therapeutics Pub Date : 2025-01-14 Epub Date: 2024-12-21 DOI:10.5582/ddt.2024.01085
Ya-Nan Ma, Xiqi Hu, Kenji Karako, Peipei Song, Wei Tang, Ying Xia
{"title":"Agarwood as a potential therapeutic for Alzheimer's disease: Mechanistic insights and target identification.","authors":"Ya-Nan Ma, Xiqi Hu, Kenji Karako, Peipei Song, Wei Tang, Ying Xia","doi":"10.5582/ddt.2024.01085","DOIUrl":null,"url":null,"abstract":"<p><p>Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, memory loss, and functional impairments. Despite extensive research, its pathogenesis remains incompletely understood, and effective treatments are limited. This study explored the therapeutic potential of agarwood in AD by integrating network pharmacology, protein-protein interaction (PPI) network analysis, and single-cell expression analysis. The results revealed that agarwood compounds may modulate key inflammatory genes such as NFKB1, STAT1, and TLR4, alleviating neuroinflammation; enhance the expression of HSP90 and regulate KDR signaling to improve blood-brain barrier (BBB) integrity; and promote the activity of PTPN11 and CXCR4 to support oligodendrocyte precursor cell (OPC) repair and remyelination. Single-cell expression analysis highlighted cell-type-specific expression patterns, particularly in OPCs and endothelial cells, underscoring their relevance in AD pathology. Agarwood's multi-dimensional therapeutic potential positions it as a promising candidate for the development of novel AD treatments.</p>","PeriodicalId":47494,"journal":{"name":"Drug Discoveries and Therapeutics","volume":" ","pages":"375-386"},"PeriodicalIF":1.5000,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Discoveries and Therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5582/ddt.2024.01085","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/21 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, memory loss, and functional impairments. Despite extensive research, its pathogenesis remains incompletely understood, and effective treatments are limited. This study explored the therapeutic potential of agarwood in AD by integrating network pharmacology, protein-protein interaction (PPI) network analysis, and single-cell expression analysis. The results revealed that agarwood compounds may modulate key inflammatory genes such as NFKB1, STAT1, and TLR4, alleviating neuroinflammation; enhance the expression of HSP90 and regulate KDR signaling to improve blood-brain barrier (BBB) integrity; and promote the activity of PTPN11 and CXCR4 to support oligodendrocyte precursor cell (OPC) repair and remyelination. Single-cell expression analysis highlighted cell-type-specific expression patterns, particularly in OPCs and endothelial cells, underscoring their relevance in AD pathology. Agarwood's multi-dimensional therapeutic potential positions it as a promising candidate for the development of novel AD treatments.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
沉香作为阿尔茨海默病的潜在治疗药物:机制见解和靶点鉴定。
阿尔茨海默病(AD)是一种进行性神经退行性疾病,以认知能力下降、记忆丧失和功能障碍为特征。尽管进行了广泛的研究,但其发病机制仍不完全清楚,有效的治疗方法也有限。本研究通过网络药理学、蛋白-蛋白相互作用(PPI)网络分析、单细胞表达分析等综合手段,探索沉香对AD的治疗潜力。结果表明沉香化合物可能调节NFKB1、STAT1、TLR4等关键炎症基因,减轻神经炎症;提高HSP90的表达,调节KDR信号,改善血脑屏障(BBB)的完整性;并促进PTPN11和CXCR4的活性,以支持少突胶质前体细胞(OPC)的修复和髓鞘再生。单细胞表达分析强调了细胞类型特异性表达模式,特别是在OPCs和内皮细胞中,强调了它们与AD病理的相关性。沉香的多维治疗潜力使其成为开发新型AD治疗方法的有希望的候选者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Drug Discoveries and Therapeutics
Drug Discoveries and Therapeutics PHARMACOLOGY & PHARMACY-
CiteScore
3.20
自引率
3.20%
发文量
51
期刊最新文献
Practical training reduces aspiration-linked gaps in pressure ulcer education for pharmacy students. Fitusiran: The first approved siRNA therapy for hemophilia via reducing plasma antithrombin levels. Silkworm (Bombyx mori) as a novel infection model for fish-derived Aeromonas hydrophila. Dietary supplementation with Nopalea cochenillifera enhances fecal mucin production and modulates serum immunoglobulin levels in a dose- and time-dependent manner in BALB/c mice. Effects of patient age on the therapeutic effects of GIP/GLP-1 receptor agonists (tirzepatide).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1